Singapore markets closed

Organon & Co. (OGN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
31.13-0.41 (-1.30%)
At close: 1:00PM EST
31.01 -0.12 (-0.39%)
After hours: 04:55PM EST
Full screen
Trade prices are not sourced from all markets
Previous close31.54
Bid31.17 x 1000
Ask31.20 x 800
Day's range30.71 - 31.60
52-week range27.25 - 38.75
Avg. volume1,879,065
Market cap7.893B
Beta (5Y monthly)N/A
PE ratio (TTM)5.21
EPS (TTM)5.97
Earnings date11 Nov 2021
Forward dividend & yield1.12 (3.55%)
Ex-dividend date19 Nov 2021
1y target est40.50
  • Business Wire

    Organon Reports Results for the Third Quarter Ended September 30, 2021

    JERSEY CITY, N.J., November 11, 2021--Organon (NYSE: OGN) (the "company"), today announced its results for the third quarter and year to date ended September 30, 2021.

  • Business Wire

    Organon to Acquire Forendo Pharma

    JERSEY CITY, N.J. & TURKU, Finland, November 11, 2021--Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral

  • CNW Group

    NEXPLANON® (etonogestrel extended-release subdermal implant) Now Covered by Quebec's Public Formulary

    Organon (NYSE: OGN) is pleased to announce NEXPLANON® (etonogestrel extended-release subdermal implant) public listing in Quebec under the Régie de l'assurance maladie du Québec (RAMQ) as of November 10. NEXPLANON® is a progestin-only hormonal implant used to prevent pregnancy for up to three years.1 Quebec is the fifth jurisdiction to list NEXPLANON® on its public formulary, including the Non-Insured Health Benefits program, Veterans Affairs Canada and the Saskatchewan Drug Plan.